High-affinity benzodiazepine antagonists reduce responding maintained by ethanol presentation in ethanol-preferring...

Area of Science:

• Neuroscience
• Pharmacology
• Addiction Research

Background:

• Ethanol (EtOH) consumption is a significant public health concern.
• Benzodiazepine (BDZ) receptors are implicated in modulating EtOH intake.
• Selective BDZ receptor antagonists offer potential therapeutic targets for alcohol use disorder.

Purpose of the Study:

• To evaluate the efficacy of two selective BDZ receptor antagonists, ZK 93426 and CGS 8216, in reducing EtOH-maintained responding in EtOH-preferring rats.
• To compare the effects of intraperitoneal and oral administration of these antagonists.
• To assess the duration of action and specificity of the observed effects.

Main Methods:

• EtOH-preferring rats were trained to press levers for EtOH or saccharin solutions under a fixed-ratio schedule.
• Rats received intraperitoneal or oral administrations of ZK 93426, CGS 8216, or flumazenil (a reference antagonist).
• Responding for EtOH and saccharin was monitored to determine the effects of the antagonists.

Main Results:

• Intraperitoneal administration of CGS 8216 and ZK 93426 dose-dependently reduced EtOH-maintained responding.
• Oral administration of higher doses of CGS 8216 and ZK 93426 also significantly decreased EtOH intake.
• Flumazenil showed minimal effects, and ZK 93426 only affected saccharin responding at the highest dose, indicating some specificity.

Conclusions:

• Selective benzodiazepine receptor antagonists ZK 93426 and CGS 8216 effectively reduce ethanol consumption in a rat model.
• These findings support the potential of BDZ antagonists as pharmacotherapies for decreasing alcohol abuse.
• Further research is warranted to explore the clinical application of these compounds in treating alcohol use disorder.